Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Acquired Rep. Robert Bresnahan, Jr.

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently bought shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). In a filing disclosed on June 09th, the Representative disclosed that they had bought between $1,001 and $15,000 in Regeneron Pharmaceuticals stock on May 15th. The trade occurred in the Representative’s “JP MORGAN BROKERAGE ACCOUNT” account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Zoom Communications (NASDAQ:ZM) on 6/25/2025.
• Purchased $1,001 – $15,000 in shares of Coinbase Global (NASDAQ:COIN) on 6/24/2025.
• Purchased $1,001 – $15,000 in shares of Circle Internet Group (NYSE:CRCL) on 6/24/2025.
• Sold $1,001 – $15,000 in shares of Amazon.com (NASDAQ:AMZN) on 6/23/2025.
• Sold $1,001 – $15,000 in shares of Chubb (NYSE:CB) on 6/13/2025.
• Sold $1,001 – $15,000 in shares of Atlassian (NASDAQ:TEAM) on 6/11/2025.
• Purchased $1,001 – $15,000 in shares of ServiceTitan (NASDAQ:TTAN) on 6/11/2025.
• Sold $1,001 – $15,000 in shares of Datadog (NASDAQ:DDOG) on 6/11/2025.
• Sold $1,001 – $15,000 in shares of GitLab (NASDAQ:GTLB) on 6/11/2025.
• Purchased $1,001 – $15,000 in shares of Broadcom (NASDAQ:AVGO) on 6/11/2025.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $545.46 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.03 and a current ratio of 4.93. The firm’s 50 day moving average price is $538.64 and its 200-day moving average price is $604.99. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $1,211.20. The company has a market cap of $58.89 billion, a PE ratio of 13.89, a P/E/G ratio of 2.08 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. The company had revenue of $3.03 billion during the quarter, compared to analysts’ expectations of $3.40 billion. During the same period in the prior year, the business posted $9.55 EPS. The company’s quarterly revenue was down 3.7% on a year-over-year basis. Sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were paid a dividend of $0.88 per share. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 8.96%.

Wall Street Analyst Weigh In

REGN has been the subject of a number of research reports. Robert W. Baird cut their target price on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a “neutral” rating for the company in a research note on Friday, April 25th. Wall Street Zen lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, May 1st. UBS Group boosted their price target on shares of Regeneron Pharmaceuticals from $560.00 to $584.00 and gave the company a “neutral” rating in a research note on Friday, July 11th. Morgan Stanley cut their target price on shares of Regeneron Pharmaceuticals from $755.00 to $754.00 and set an “overweight” rating on the stock in a research note on Thursday, July 10th. Finally, Wells Fargo & Company downgraded shares of Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and cut their target price for the stock from $700.00 to $580.00 in a research note on Friday, May 30th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $837.61.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of REGN. Vanguard Group Inc. grew its holdings in Regeneron Pharmaceuticals by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company’s stock worth $5,966,767,000 after acquiring an additional 121,545 shares during the last quarter. Capital International Investors raised its position in shares of Regeneron Pharmaceuticals by 41.6% in the 4th quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company’s stock valued at $3,373,859,000 after acquiring an additional 1,390,534 shares during the period. Geode Capital Management LLC raised its position in shares of Regeneron Pharmaceuticals by 6.8% in the 4th quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company’s stock valued at $1,726,940,000 after acquiring an additional 155,369 shares during the period. Dodge & Cox raised its position in shares of Regeneron Pharmaceuticals by 0.4% in the 4th quarter. Dodge & Cox now owns 2,321,316 shares of the biopharmaceutical company’s stock valued at $1,653,543,000 after acquiring an additional 9,381 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its holdings in Regeneron Pharmaceuticals by 4.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,175,026 shares of the biopharmaceutical company’s stock worth $1,379,467,000 after buying an additional 89,579 shares during the period. Institutional investors own 83.31% of the company’s stock.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania’s 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania’s 8th Congressional District. He declared candidacy for the 2026 election.

Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.